Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.
Nicolas Gower, Pierre Feugier, Jason Westin, Jean-Marc Schiano De Colella, Hervé Tilly, M Lia Palomba, Edith Julia, Gandhi-Laurent Damaj, Amandine Durand, Ian Flinn, François Lemonnier, Nadine Morineau, Loic Ysebaert, Nancy Bartlett, Catherine Thieblemont, Vincent Ribrag, Thomas Gastinne, Arthur Dony, Ludovic Fouillet, Stephanie Guidez, Roch Houot, Maria Gomes Da Silva, Jeffrey Barnes, Fontanet Bijou, Guillaume Cartron, Alejandro Martin Garcia-Sancho, Herbert Eradat, Morgane Cheminant, Armando Lopez Guillermo, Pau Abrisqueta, Julie Abraham, Clémentine Sarkozy, Koji Izutsu, Gilles Crochet, Laurie H Sehn, Argyrios Gkasiamis, Marie Laurence Yge, Loic Chartier, Nathan Fowler, Luc Xerri, Gilles Salles, Franck Morschhauser
Blood 147(25) 3061-3068
摘要
摘要
In the multinational, phase 3 RELEVANCE trial, 1030 patients with previously untreated follicular lymphoma were randomized to receive rituximab + lenalidomide (R2; n = 513) or rituximab-based immunochemotherapy (R-Chemo; n = 517). In the final analysis, at 120 months of follow-up, median progression-free survival (PFS) was comparable between the treatment groups: 110.6 months with R2 vs 102.8 months with R-Chemo, according to the independent review committee assessment. The 10-year PFS rates were 46.4% for R2 and 46.6% for R-chemo. Median overall survival (OS) and time-to-next lymphoma treatment (TTNLT) were not reached in either arm; 10-year OS rates were 82.4% for R2 and 81.1% for R-chemo, and 10-year TTNLT rates were 62.2% for R2 and 66.3% for R-chemo. Overall, patients with progression of disease within 24 months (POD24) had a poorer prognosis than those without POD24 (hazard ratio, 6.215; P< .0001); however, no difference was observed between the study groups. The incidence of second primary malignancies (SPMs) was 2.11 cases per 100 patient-years (95% confidence interval, 1.80-2.46). Only 9 transformations occurred after 24 months (3 with R2 vs 6 with R-chemo). In each study group, 87 patients died, mainly because of lymphoma progression and SPMs. This long-term follow-up of RELEVANCE confirmed that R2 provides a chemotherapy-free alternative to immunochemotherapy in this patient population. This trial was registered at www.clinicaltrials.gov as NCT01476787 and NCT01650701 and at EudraCT as 2011-002792-42.
KM 提取结果
0 个 Figure · 0 个 KM 面板